Novel saRNA Therapy Boosts Heart's Natural Healing After Attack

Researchers have developed a novel self-amplifying RNA (saRNA) therapy designed to enhance the heart's natural healing process after a heart attack. Delivered via a minimally invasive injection, this innovative therapy aims to reduce scarring and improve cardiac function. Initial findings in animal models, detailing the approach, were recently published in the prestigious journal Science.

Understanding the Challenge of Heart Attack Recovery

Following a heart attack, the heart muscle sustains significant injury, leading to scarring and an irreversible loss of healthy tissue. Unlike many other organs, the heart has limited regenerative capacity, meaning lost muscle cells are rarely replaced.

While the body naturally produces atrial natriuretic peptide (ANP)—a hormone crucial for reducing stress on the heart and limiting long-term damage—its production is often insufficient to significantly impact recovery. Current therapies do not fully prevent the progressive weakening of the heart over time due to scarring, a major clinical challenge.

The Novel RNA-Based Therapy

The new therapy leverages cutting-edge self-amplifying RNA (saRNA) technology. This innovative approach provides temporary genetic instructions to muscle cells. When injected into skeletal muscle, such as in the arm or thigh, these instructions direct the cells to produce pro-ANP, a non-reactive precursor to the beneficial ANP hormone.

This pro-ANP then circulates harmlessly through the bloodstream. Crucially, upon reaching the heart, it encounters an enzyme called Corin, which is present at higher levels in cardiac tissue. Corin converts pro-ANP into its active form, ensuring the therapeutic agent becomes active precisely where it is needed. The saRNA technology enables sustained pro-ANP production, with a single injection proving effective for at least four weeks in studies.

ANP is known to promote new blood vessel growth, reduce inflammation, and minimize scar formation, significantly contributing to the heart's natural repair mechanisms.

Research Inspiration and Development

The research drew critical inspiration from the remarkable regenerative capabilities observed in newborn mammal hearts, which naturally produce higher levels of ANP after injury. Experiments comparing newborn and adult mice revealed that the gene (Nppa) responsible for producing ANP's precursor increased significantly more in newborns following a heart attack. Blocking Nppa in newborn mice was observed to reduce their hearts' healing ability, underscoring its importance.

Despite ANP's recognized potential for decades, its short half-life in the body has historically made it unsuitable as a conventional drug therapy. This new minimally invasive injection method represents a significant advancement from earlier research, which explored localized delivery via a microneedle patch for heart surface application or approaches requiring open-chest surgery. The current therapy is designed for broader clinical use through a standard injection.

Study Findings and Potential Impact

Laboratory experiments, including those conducted on both small and large animal models, demonstrated compelling results. A single injection of the saRNA therapy consistently led to reduced scarring and improved heart function. The therapy's efficacy was rigorously tested across various animal models, including aged mice, mice with pre-existing conditions like atherosclerosis and type 2 diabetes, and with delayed treatment after a heart attack, consistently showing effectiveness.

Researchers aim for this therapy to protect the heart during its vulnerable post-attack phase, potentially altering the recovery trajectory for patients by reducing scarring, preserving healthy heart muscle, improving cardiac pumping function, and decreasing the risk of long-term complications such as heart failure.

Collaborative Research and Future Directions

Key researchers involved in this groundbreaking work include Dr. Ke Huang, an assistant professor at the Texas A&M Irma Lerma Rangel College of Pharmacy, and Ke Cheng, the Alan L. Kaganov Professor of Biomedical Engineering at Columbia Engineering, along with Dr. Torsten Vahl, a physician at Columbia University Irving Medical Center. The research involved collaborative partnerships with Columbia University and the University of Oxford.

The research team plans to conduct further studies on the therapy's safety, optimal timing, and dosing. Manufacturing of the therapy is planned at the Columbia Initiative in Cell Engineering and Therapy, with a phase-one safety trial anticipated at Columbia University Irving Medical Center before progressing to broader human trials. This innovative saRNA delivery method may also hold significant potential applications for other conditions involving cell damage, such as kidney disease, high blood pressure, and preeclampsia.